Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ALT - Altimmune, Inc.

IEX Last Trade
7.555
0.125   1.655%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$7.43
0.13
1.68%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
13%
Profitability 8%
Dept financing 5%
Liquidity 50%
Performance 11%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.48%
1 Month
-11.90%
3 Months
7.86%
6 Months
1.89%
1 Year
-18.55%
2 Year
-50.75%
Key data
Stock price
$7.56
P/E Ratio 
0.00
DAY RANGE
$7.43 - $7.71
EPS 
$0.00
52 WEEK RANGE
$5.93 - $14.84
52 WEEK CHANGE
-$33.48
MARKET CAP 
476.175 M
YIELD 
N/A
SHARES OUTSTANDING 
71.071 M
DIVIDEND
$2.91
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
2.09
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,174,364
AVERAGE 30 VOLUME 
$3,301,515
Company detail
CEO: Vipin K. Garg
Region: US
Website: altimmune.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Altimmune, Inc. focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.

Recent news